Page 2 Line 54: This needs clarification here, and in the body. If you are looking at whether pain and function have different courses, how does one differentiate by function that is altered by pain? Even after pain has subsided, many patients who have had pain for weeks or longer have altered function and movement, and neuroplastic changes have taken place that alter the recruitment of muscle groups for movement, even when movement is planned or perceived. How will this review incorporate that aspect of function that has been altered by the experience of pain, after pain has eased? Can this be addressed in selection criteria or described more?
Page 3 Line 5: There is not a description or critical overview of current evidence. Even in the protocol, this is an important feature to have, giving a background to this review and why the questions being asked have not been addressed. Page 6 Line 55: Search strategy: The search strategy for studies published only in English is questionable. It raises the possibility of missing significant data from studies that might not have been translated into English, or whose titles have been mistranslated. Given the ease of using commercially available and free-access translation services, including Google translate, it is important not to limit the language to English only. It may be that limiting inclusion to articles in English and languages other than English that can be translated with such systems will produce a more accurate picture of the available evidence.
Page 6 Line 10: It would be a good idea to include a grey literature search in some portal specific for grey literature. A great deal may be published in grey literature, from conference papers to clinical trials and government reports. Some of the databases cited may capture some aspects, but none of the ones listed do well. Scopus, for example, may catch clinical trials but does not include MeSH and Emtree index terms, which limits its value for systematic review searching. Also, will there be a language restriction on the search? Page 6 Line 57: Will you be comparing control with no treatment, standard of care... separately? Will these be explored by subgroup analysis later? Page 7 Line 5: Is constant mean to be consistent? Page 6 Lines 6-11: Is the goal of the systematic review to describe the natural course and the clinical course of SSP separately, in comparison to each other, or together? This is the question I also had reading the abstract.
Page 8 Line 13: Please explain why patients receiving placebo or sham treatment are excluded? This needs to be elaborated so the reader understands the reasoning, even in a protocol. Page 10 Lines 44-58: This area needs major revision. There is no detail here allowing it to be understood what statistical measures, processes and tools will be used. This is an important part of the protocol and a very important part of a systematic review and metaanalysis. What software or program will you use for this? How will this be done? Who will do it? What will be your measures for heterogeneity, and thresholds for low, moderate, high, too much...? Will you use fixed or random effects meta-analysis if you are able to do meta-analysis? How will you decide how many studies are enough for meta-regression? Typically, at least 10 are needed. What software will you use for meta-regression? Not all software packages will allow for meta-regression. If so, what will be the dependent and independent variables if so? These are important components that need to be described in the protocol and determined, a priori, where possible. Even if you may end up not doing meta-analysis, you have said that you may, and so this must all be included in the protocol.
Page 11 Lines 6-17: These sound more like sub-group analyses than sensitivity analyses. What sensitivity analyses will be included? Will they include the potential effects of levels of heterogeneity, date of publication....? For example. sensitivity analysis could take place comparing the results when including all studies where the eligibility criteria or interventions were fully reported, and then when studies where additional, non-published information (provided by the author, or calculated by your team) were included. This needs to be considered and described if it is part of the plan. The Cochrane handbook may be a good source for these: http://handbook-5-1.cochrane.org/chapter_9/9_7_sensitivity_analyses.htm Page 11 Line 38: This just needs a bit of a re-wording. It will establish the clinical course of SPS when there is no care, and also when standard care is given? If standard care is very variable across the broad range of settings, provider preferences and experiences likely in practice and across different locations, is this comparison to "standard care" possible, valid, or useful? I can see the benefit of having a clinical course when no intervention takes place, but unless you can somehow group "standards of care" into groups, and describe the course of those separately, i don't see how that comparison to "standard of care" will be possible. This just needs to be rethought or re-described.
VERSION 1 -AUTHOR RESPONSE
Editorial request Please correct the grammatical error in the title (protocol of systematic review => protocol for a systematic review) Response: Corrected: page 15, line 7.
Please correct the PROSPERO registration number on page 3 (RD42016052518 => CRD42016052518). Response: Corrected, page 16 line 52. Reviewer 1 Introduction should be enlarged with more up-to-date information related to the course of the shoulder pain.
Response: Thank you, we revised the introduction. (page 17, lines 26 to 57).
Reviewer 2 Page 2 Line 34: Meta-regression needs a minimum number of studies, typically greater than 10 studies. You say if you have more than 2 with acceptable heterogeneity, you will do meta-regression, but this would not be appropriate with less than 10. This needs to be considered. Response: Yes, you are correct, we revised this section. (page 23, lines 41 to 56; page 24, lines 6 to 17). We will use meta-regression if we find more than 10 studies in no intervention or usual care group. If we have less than 10 studies in each group, we will use meta-analysis to estimate pain or functional scores over time. We have revised the text to address to improve clarity. Page 2 Line 54: This needs clarification here, and in the body. If you are looking at whether pain and function have different courses, how does one differentiate by function that is altered by pain? Even after pain has subsided, many patients who have had pain for weeks or longer have altered function and movement, and neuroplastic changes have taken place that alter the recruitment of muscle groups for movement, even when movement is planned or perceived. How will this review incorporate that aspect of function that has been altered by the experience of pain. Response: The aim of this comparison is to assess whether function and pain levels have different recovery rates. As you have highlighted, patients may present changes in pain, but not in function scores. Through this analysis, we will report whether or not pain and function have similar or different recovery rates. This information will be valuable for future studies exploring the potential mechanisms for such difference (if existent). Some of these mechanisms might be the ones you have highlighted in your comments. In our analysis, we will not be able to assess the underlying mechanisms for such differences (if present). We hypothesize that the clinical course of pain will be more favourable than function. This section was revised in the abstract (page 16, line 21), and in the main text (page 23, lines 29 to 36).
Page 3 Line 5: There is not a description or critical overview of current evidence. Even in the protocol, this is an important feature to have, giving a background to this review and why the questions being asked have not been addressed. Response: We have revised the introduction, and included additional information highlighting the rationale and necessity of conducting this systematic review (page 17, lines 30 to 57).
Page 6 Line 55: Search strategy: The search strategy for studies published only in English is questionable. It raises the possibility of missing significant data from studies that might not have been translated into English, or whose titles have been mistranslated. Given the ease of using commercially available and free-access translation services, including Google translate, it is important not to limit the language to English only. It may be that limiting inclusion to articles in English and languages other than English that can be translated with such systems will produce a more accurate picture of the available evidence. Response: We appreciate your interest in our study and your suggestion to broaden the search to non-English citations. Following your recommendation, the research team decided to include studies with other languages as well. We revised this section (page 18, line 48).
Page 6 Line 10: It would be a good idea to include a grey literature search in some portal specific for grey literature. A great deal may be published in grey literature, from conference papers to clinical trials and government reports. Some of the databases cited may capture some aspects, but none of the ones listed do well. Scopus, for example, may catch clinical trials but does not include MeSH and Emtree index terms, which limits its value for systematic review searching. Also, will there be a language restriction on the search? Response: Thank you for your suggestion. We will consider including grey literature, if they report information about participants' characteristics, study design, and raw data. Regarding search strategy and Scopus database, we consulted again with librarian who reassured us the search strategy was comprehensive. Scopus encompasses a large amount of grey literature (including conference proceedings). Hence, we believe our search is thorough and appropriate for the aim of this review. As an example, the search strategy planned for our review includes a larger number of databases if compared to a previous review on clinical course of pain and disability on patients with low back pain [1] .
Page 6 Line 57: Will you be comparing control with no treatment, standard of care... separately? Will these be explored by subgroup analysis later? Response: We will not compare control with no treatment or standard care. But we will conduct subanalysis later, based on these groups. Page 7 Line 5: Is constant mean to be consistent? Response: Correct. We revised the text (page 19, line 31).
Page 6 Lines 6-11: Is the goal of the systematic review to describe the natural course and the clinical course of SSP separately, in comparison to each other, or together? This is the question I also had reading the abstract. Response: Our primary aim is to assess the clinical course of pain and function in in patients with shoulder pain. Initially, we were planning to assess the natural course of shoulder pain. However, after conducting preliminary searchers, we quickly realized it would be very difficult to obtain pure observational studies with participants not exposed to any form of intervention. For that reason, we opted to explore the clinical course of subacromial shoulder pain and had to include studies that offered 'usual care' or 'no intervention' to participants. The advantage of including these studies is to summarize the clinical course of patients who receive some forms of intervention.
Page 8 Line 13: Please explain why patients receiving placebo or sham treatment are excluded? This needs to be elaborated so the reader understands the reasoning, even in a protocol. heterogeneity, ranging between "30-60%" as moderate, "60 to 90%" as substantial and "90 to 100%" as considerable heterogeneity [4] . The text was revised to enhance clarity (page 24, lines 6 to 17).
Page 11 Lines 6-17: These sound more like sub-group analyses than sensitivity analyses. What sensitivity analyses will be included? Will they include the potential effects of levels of heterogeneity, date of publication....? For example. Sensitivity analysis could take place comparing the results when including all studies where the eligibility criteria or interventions were fully reported, and then when studies where additional, non-published information (provided by the author, or calculated by your team) were included. This needs to be considered and described if it is part of the plan. The Cochrane handbook may be a good source for these: http://handbook-5-1.cochrane.org/chapter_9/9_7_sensitivity_analyses.htm Response: Correct, we changed this section to sub analysis (page 24, lines 22 to 35). We do not have any plan to do sensitivity analysis.
Page 11 Line 38: This just needs a bit of a re-wording. It will establish the clinical course of SPS when there is no care, and also when standard care is given? If standard care is very variable across the broad range of settings, provider preferences and experiences likely in practice and across different locations, is this comparison to "standard care" possible, valid, or useful? I can see the benefit of having a clinical course when no intervention takes place, but unless you can somehow group "standards of care" into groups, and describe the course of those separately, i don't see how that comparison to "standard of care" will be possible. This just needs to be rethought or redescribed. Response: We may conduct sub-analysis based on the type of usual care offered to patients, as for example treatment offered by GPs, or physiotherapists. If we cannot conduct a sub-analysis within the usual care interventions, we will describe the clinical course of pain and function individually (page 24, lines 28-35).
In the Prisma statement item 16: You have written n/a, but this is not the case. It is very applicable to any systematic review, and indeed, very important. You can also use a funnel plot on RevMan5 to assess this visually, as you will be using that to do meta-analysis. That item should be rewritten, as you should be considering the potential for publication bias.
Lines 166-175: This is excellent and an important addition! Line 193: "If less than 10 studies are identified, we will conduct meta-analysis according to time categories" It needs to be described more clearly what meta-analysis you will do. Will you be pooling estimates of x or y or z? Or, producing estimates of risk of pain or functional disability measures...? Just keep in mind also, that do do meta-regression, you have to do meta-analysis. Meta-regression can be implemented following a traditional meta-analysis and can be thought of as an extension to it. Given that, it would be worth considering saying you will do meta-analysis, and meta-regression if sufficient... By pooling any estimates or measuring heterogeneity, you are doing meta-analysis, and can't really do meta-regression without it.
Line 196: "The meta-analysis will be pooled the estimates of change in pain or function in each time category. " This sentence needs to be revised, as does not make sense as is.
Line 199: This was a good addition. Please include a simple statement about why you are choosing a random effects model. Is it because you expect any kind of clinical heterogeneity among participants and studies, for example?
Line 206: "analysis is not possible, we will we will present a narrative discussion based on findings from " This needs to be edited. This was much improved. Please just give another look to catch minor editing errors, such as those in lines 196 and 206. Also, the meta-analysis section would benefit from the clarifications suggested above. Having done this, I think this will be ready for acceptance.
VERSION 2 -AUTHOR RESPONSE
Dear Dr Trish Groves, Dr. Arsenio Paez, Dr Edward Sucksmith, Thank you for your feedback and suggestions, and for the opportunity to revise our manuscript. We believe it now has improved its clarity, and hope it corresponds to your expectations.
Best regards, The authors
Editorial Requests: Please revise your abstract so that it is following journal guidelines (see: http://bmjopen.bmj.com/pages/authors/#study_protocols). For example the first paragraph does not contain a heading. This should be 'Introduction'. The next section should be labeled as 'Methods and analysis' and there should be a final section called 'Ethics and Dissemination'. We recommend taking a look at the abstracts of other systematic review protocols published in the journal as examples. Please remember to add your dissemination plans to the 'Ethics and Dissemination' section.
Line 206: "analysis is not possible, we will we will present a narrative discussion based on findings from " This needs to be edited. Response: We edited. Page 10 line 216.
VERSION 3 -REVIEW REVIEWER
Dr. Arsenio Paez University of Oxford, Oxford, UK Northeastern University, Boston, MA, USA REVIEW RETURNED 22-Feb-2018
GENERAL COMMENTS
Thank you for revising this protocol, which is much improved and will be of great interest to readers.
VERSION 3 -AUTHOR RESPONSE Dear Editor and Reviewers
Thank you for all the comments for improving the concept of this protocol. While revising this manuscript, we noticed we had initially included quality of life as a secondary outcome measure, but we did not include this as part of the aim of the study neither as part of the planned statistical analysis. Hence, we decided to exclude the "quality of lite" as a secondary outcome measure for this review. We have deleted this, but would like to confirm you are in agreement with this decision.
We have revised the text according to your recommendations, and hope the revised manuscript corresponds to your expectations.
Below we present a response for each comment raised by the editorial team.
Best regards, The authors.
Editorial Comments and Requests:
